Download Files:
AG-270
$380 – $2,850
Products Details
Product Description
– AG-270 is an allosteric, noncompetitive, first-in-class, reversible and orally active MAT2A inhibitor, with an IC50 of 14 nM[1].
Web ID
– HY-138630
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C30H27N5O2
References
– [1]Zenon Konteatis, et al. Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous MTAP Deletion. J Med Chem. 2021 Apr 8.|[2]Marc L Hyer, et al. The MAT2A inhibitor AG-270 combines with both taxanes and gemcitabine to yield enhanced antitumor activity in patient-derived xenograft models.
CAS Number
– 2201056-66-6
Molecular Weight
– 489.57
Compound Purity
– 99.88
SMILES
– O=C1C(C2=CC=C(OC)C=C2)=C(NC3=NC=CC=C3)NC4=C(C5=CCCCC5)C(C6=CC=CC=C6)=NN14
Clinical Information
– Phase 1
Research Area
– Cancer
Solubility
– DMSO : 4 mg/mL (ultrasonic;warming;heat to 60°C)
Target
– Methionine Adenosyltransferase (MAT)
Pathway
– Epigenetics;Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
